0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gene Therapy for Sickle Cell Disease Market Research Report 2026
Published Date: 2026-02-10
|
Report Code: QYRE-Auto-9V18477
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Gene Therapy for Sickle Cell Disease Market Research Report 2024
BUY CHAPTERS

Global Gene Therapy for Sickle Cell Disease Market Research Report 2026

Code: QYRE-Auto-9V18477
Report
2026-02-10
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Gene Therapy for Sickle Cell Disease Market

The global Gene Therapy for Sickle Cell Disease market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Gene therapy for sickle cell disease is a treatment that aims to correct the genetic mutation responsible for producing abnormal hemoglobin, which leads to sickle-shaped red blood cells. This process involves extracting the patient's hematopoietic stem cells, introducing a functional copy of the β-globin gene to restore normal hemoglobin production, and reinfusing the modified cells back into the patient.The goal is to alleviate symptoms and complications of the disease, such as pain crises and anemia, potentially offering a long-term cure for affected individuals.
The North American market for Gene Therapy for Sickle Cell Disease is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Gene Therapy for Sickle Cell Disease is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Gene Therapy for Sickle Cell Disease in Children and Adolescents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Gene Therapy for Sickle Cell Disease include Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Gene Therapy for Sickle Cell Disease market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gene Therapy for Sickle Cell Disease. The Gene Therapy for Sickle Cell Disease market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Gene Therapy for Sickle Cell Disease market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gene Therapy for Sickle Cell Disease manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Gene Therapy for Sickle Cell Disease Market Report

Report Metric Details
Report Name Gene Therapy for Sickle Cell Disease Market
Segment by Type
  • Gene Addition Therapies
  • Gene Editing Therapies
  • Others
Segment by Application
  • Children and Adolescents
  • Adults
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Gene Therapy for Sickle Cell Disease companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The main players in the Gene Therapy for Sickle Cell Disease Market are Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics

What are the Application segmentation covered in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The Applications covered in the Gene Therapy for Sickle Cell Disease Market report are Children and Adolescents, Adults

What are the Type segmentation covered in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The Types covered in the Gene Therapy for Sickle Cell Disease Market report are Gene Addition Therapies, Gene Editing Therapies, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Gene Addition Therapies
1.2.3 Gene Editing Therapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Gene Therapy for Sickle Cell Disease Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Children and Adolescents
1.3.3 Adults
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Sickle Cell Disease Market Perspective (2021–2032)
2.2 Global Gene Therapy for Sickle Cell Disease Growth Trends by Region
2.2.1 Global Gene Therapy for Sickle Cell Disease Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Gene Therapy for Sickle Cell Disease Historic Market Size by Region (2021–2026)
2.2.3 Gene Therapy for Sickle Cell Disease Forecasted Market Size by Region (2027–2032)
2.3 Gene Therapy for Sickle Cell Disease Market Dynamics
2.3.1 Gene Therapy for Sickle Cell Disease Industry Trends
2.3.2 Gene Therapy for Sickle Cell Disease Market Drivers
2.3.3 Gene Therapy for Sickle Cell Disease Market Challenges
2.3.4 Gene Therapy for Sickle Cell Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Sickle Cell Disease Players by Revenue
3.1.1 Global Top Gene Therapy for Sickle Cell Disease Players by Revenue (2021–2026)
3.1.2 Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Players (2021–2026)
3.2 Global Top Gene Therapy for Sickle Cell Disease Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Gene Therapy for Sickle Cell Disease Revenue
3.4 Global Gene Therapy for Sickle Cell Disease Market Concentration Ratio
3.4.1 Global Gene Therapy for Sickle Cell Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Sickle Cell Disease Revenue in 2025
3.5 Global Key Players of Gene Therapy for Sickle Cell Disease Head Offices and Areas Served
3.6 Global Key Players of Gene Therapy for Sickle Cell Disease, Products and Applications
3.7 Global Key Players of Gene Therapy for Sickle Cell Disease, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Gene Therapy for Sickle Cell Disease Breakdown Data by Type
4.1 Global Gene Therapy for Sickle Cell Disease Historic Market Size by Type (2021–2026)
4.2 Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Type (2027–2032)
5 Gene Therapy for Sickle Cell Disease Breakdown Data by Application
5.1 Global Gene Therapy for Sickle Cell Disease Historic Market Size by Application (2021–2026)
5.2 Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Gene Therapy for Sickle Cell Disease Market Size (2021–2032)
6.2 North America Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Gene Therapy for Sickle Cell Disease Market Size by Country (2021–2026)
6.4 North America Gene Therapy for Sickle Cell Disease Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Sickle Cell Disease Market Size (2021–2032)
7.2 Europe Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2021–2026)
7.4 Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size (2021–2032)
8.2 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2021–2026)
8.4 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Gene Therapy for Sickle Cell Disease Market Size (2021–2032)
9.2 Latin America Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2021–2026)
9.4 Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size (2021–2032)
10.2 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2021–2026)
10.4 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Details
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals Gene Therapy for Sickle Cell Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Bluebird bio
11.2.1 Bluebird bio Company Details
11.2.2 Bluebird bio Business Overview
11.2.3 Bluebird bio Gene Therapy for Sickle Cell Disease Introduction
11.2.4 Bluebird bio Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.2.5 Bluebird bio Recent Development
11.3 Editas Medicine
11.3.1 Editas Medicine Company Details
11.3.2 Editas Medicine Business Overview
11.3.3 Editas Medicine Gene Therapy for Sickle Cell Disease Introduction
11.3.4 Editas Medicine Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.3.5 Editas Medicine Recent Development
11.4 CRISPR Therapeutics
11.4.1 CRISPR Therapeutics Company Details
11.4.2 CRISPR Therapeutics Business Overview
11.4.3 CRISPR Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.4.4 CRISPR Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.4.5 CRISPR Therapeutics Recent Development
11.5 Beam Therapeutics
11.5.1 Beam Therapeutics Company Details
11.5.2 Beam Therapeutics Business Overview
11.5.3 Beam Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.5.4 Beam Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.5.5 Beam Therapeutics Recent Development
11.6 Intellia Therapeutics
11.6.1 Intellia Therapeutics Company Details
11.6.2 Intellia Therapeutics Business Overview
11.6.3 Intellia Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.6.4 Intellia Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2021–2026)
11.6.5 Intellia Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Gene Addition Therapies
 Table 3. Key Players of Gene Editing Therapies
 Table 4. Key Players of Others
 Table 5. Global Gene Therapy for Sickle Cell Disease Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Gene Therapy for Sickle Cell Disease Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global Gene Therapy for Sickle Cell Disease Market Size by Region (US$ Million), 2021–2026
 Table 8. Global Gene Therapy for Sickle Cell Disease Market Share by Region (2021–2026)
 Table 9. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 10. Global Gene Therapy for Sickle Cell Disease Market Share by Region (2027–2032)
 Table 11. Gene Therapy for Sickle Cell Disease Market Trends
 Table 12. Gene Therapy for Sickle Cell Disease Market Drivers
 Table 13. Gene Therapy for Sickle Cell Disease Market Challenges
 Table 14. Gene Therapy for Sickle Cell Disease Market Restraints
 Table 15. Global Gene Therapy for Sickle Cell Disease Revenue by Players (US$ Million), 2021–2026
 Table 16. Global Gene Therapy for Sickle Cell Disease Market Share by Players (2021–2026)
 Table 17. Global Top Gene Therapy for Sickle Cell Disease Players by Tier (Tier 1, Tier 2, and Tier 3), based on Gene Therapy for Sickle Cell Disease Revenue, 2025
 Table 18. Ranking of Global Top Gene Therapy for Sickle Cell Disease Companies by Revenue (US$ Million) in 2025
 Table 19. Global 5 Largest Players Market Share by Gene Therapy for Sickle Cell Disease Revenue (CR5 and HHI), 2021–2026
 Table 20. Global Key Players of Gene Therapy for Sickle Cell Disease, Headquarters and Area Served
 Table 21. Global Key Players of Gene Therapy for Sickle Cell Disease, Products and Applications
 Table 22. Global Key Players of Gene Therapy for Sickle Cell Disease, Date of General Availability (GA)
 Table 23. Mergers and Acquisitions, Expansion Plans
 Table 24. Global Gene Therapy for Sickle Cell Disease Market Size by Type (US$ Million), 2021–2026
 Table 25. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Type (2021–2026)
 Table 26. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 27. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Type (2027–2032)
 Table 28. Global Gene Therapy for Sickle Cell Disease Market Size by Application (US$ Million), 2021–2026
 Table 29. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Application (2021–2026)
 Table 30. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 31. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Application (2027–2032)
 Table 32. North America Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 33. North America Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2021–2026
 Table 34. North America Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2027–2032
 Table 35. Europe Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 36. Europe Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2021–2026
 Table 37. Europe Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2027–2032
 Table 38. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 39. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (US$ Million), 2021–2026
 Table 40. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (US$ Million), 2027–2032
 Table 41. Latin America Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2021–2026
 Table 43. Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2027–2032
 Table 44. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2021–2026
 Table 46. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (US$ Million), 2027–2032
 Table 47. Vertex Pharmaceuticals Company Details
 Table 48. Vertex Pharmaceuticals Business Overview
 Table 49. Vertex Pharmaceuticals Gene Therapy for Sickle Cell Disease Product
 Table 50. Vertex Pharmaceuticals Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 51. Vertex Pharmaceuticals Recent Development
 Table 52. Bluebird bio Company Details
 Table 53. Bluebird bio Business Overview
 Table 54. Bluebird bio Gene Therapy for Sickle Cell Disease Product
 Table 55. Bluebird bio Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 56. Bluebird bio Recent Development
 Table 57. Editas Medicine Company Details
 Table 58. Editas Medicine Business Overview
 Table 59. Editas Medicine Gene Therapy for Sickle Cell Disease Product
 Table 60. Editas Medicine Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 61. Editas Medicine Recent Development
 Table 62. CRISPR Therapeutics Company Details
 Table 63. CRISPR Therapeutics Business Overview
 Table 64. CRISPR Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 65. CRISPR Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 66. CRISPR Therapeutics Recent Development
 Table 67. Beam Therapeutics Company Details
 Table 68. Beam Therapeutics Business Overview
 Table 69. Beam Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 70. Beam Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 71. Beam Therapeutics Recent Development
 Table 72. Intellia Therapeutics Company Details
 Table 73. Intellia Therapeutics Business Overview
 Table 74. Intellia Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 75. Intellia Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (US$ Million), 2021–2026
 Table 76. Intellia Therapeutics Recent Development
 Table 77. Research Programs/Design for This Report
 Table 78. Key Data Information from Secondary Sources
 Table 79. Key Data Information from Primary Sources
 Table 80. Authors List of This Report


List of Figures
 Figure 1. Gene Therapy for Sickle Cell Disease Picture
 Figure 2. Global Gene Therapy for Sickle Cell Disease Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Gene Therapy for Sickle Cell Disease Market Share by Type: 2025 vs 2032
 Figure 4. Gene Addition Therapies Features
 Figure 5. Gene Editing Therapies Features
 Figure 6. Others Features
 Figure 7. Global Gene Therapy for Sickle Cell Disease Market Size by Application (US$ Million), 2021–2032
 Figure 8. Global Gene Therapy for Sickle Cell Disease Market Share by Application: 2025 vs 2032
 Figure 9. Children and Adolescents Case Studies
 Figure 10. Adults Case Studies
 Figure 11. Gene Therapy for Sickle Cell Disease Report Years Considered
 Figure 12. Global Gene Therapy for Sickle Cell Disease Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 13. Global Gene Therapy for Sickle Cell Disease Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 14. Global Gene Therapy for Sickle Cell Disease Market Share by Region: 2025 vs 2032
 Figure 15. Global Gene Therapy for Sickle Cell Disease Market Share by Players in 2025
 Figure 16. Global Gene Therapy for Sickle Cell Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 17. The Top 10 and 5 Players Market Share by Gene Therapy for Sickle Cell Disease Revenue in 2025
 Figure 18. North America Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 19. North America Gene Therapy for Sickle Cell Disease Market Share by Country (2021–2032)
 Figure 20. United States Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Canada Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Gene Therapy for Sickle Cell Disease Market Share by Country (2021–2032)
 Figure 24. Germany Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. France Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. U.K. Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Italy Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Russia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Ireland Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Share by Region (2021–2032)
 Figure 32. China Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Japan Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. South Korea Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Southeast Asia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. India Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Australia & New Zealand Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Gene Therapy for Sickle Cell Disease Market Share by Country (2021–2032)
 Figure 40. Mexico Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Brazil Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Share by Country (2021–2032)
 Figure 44. Israel Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Saudi Arabia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. UAE Gene Therapy for Sickle Cell Disease Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Vertex Pharmaceuticals Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 48. Bluebird bio Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 49. Editas Medicine Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 50. CRISPR Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 51. Beam Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 52. Intellia Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2021–2026)
 Figure 53. Bottom-up and Top-down Approaches for This Report
 Figure 54. Data Triangulation
 Figure 55. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS